Scholarlink

Objective <p>To screen high-risk infants for CP in a level IV NICU and high-risk infant follow-up (HRIF) clinic.</p> Study Design <p>By using quality improvement methodology, we implemented the General Movement Assessment (GMA) and Hammersmith Infant Neurological Examination (HINE) to screen for CP and lower age at diagnosis. Main balancing measures included no-show rates.</p> Results <p>Within the first year, 89% of infants had a GMA in the NICU, 100% in HRIF and 87% had a HINE in HRIF. Median age at diagnosis decreased from 18.5 months adjusted [16.7,19.4] in 2021 to 7.5 months [5.9,14.4; <i>p</i> = 0.01] in 2022 and 8.9 months [6.6,12.2; <i>p</i> = 0.01] in 2023. No-show rates increased in 2022 compared to 2021 (24% vs 17%, <i>p</i> = 0.02).</p> Conclusions <p>By implementing and continuously improving a standard process in the NICU and HRIF, we demonstrated a successful increase in screening for CP leading to a lower age at diagnosis sustained for two years.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Standardizing early cerebral palsy detection in high-risk infants: reducing age at diagnosis through a quality improvement initiative

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月9日

查看全文
  • Sylvan Ryder,
  • Mallory Kerner-Rossi,
  • Sandhya Brachio,
  • Lisa Yoon,
  • Kathleen Brennan,
  • Jennifer Hammond,
  • Gabriella Paskin,
  • Annette Zygmunt,
  • Anketil Abreu,
  • Shelagh O’Neill,
  • Patricia Ryan,
  • Joan Wagner,
  • Anna Penn,
  • Faith Kim

摘要

Objective

To screen high-risk infants for CP in a level IV NICU and high-risk infant follow-up (HRIF) clinic.

Study Design

By using quality improvement methodology, we implemented the General Movement Assessment (GMA) and Hammersmith Infant Neurological Examination (HINE) to screen for CP and lower age at diagnosis. Main balancing measures included no-show rates.

Results

Within the first year, 89% of infants had a GMA in the NICU, 100% in HRIF and 87% had a HINE in HRIF. Median age at diagnosis decreased from 18.5 months adjusted [16.7,19.4] in 2021 to 7.5 months [5.9,14.4; p = 0.01] in 2022 and 8.9 months [6.6,12.2; p = 0.01] in 2023. No-show rates increased in 2022 compared to 2021 (24% vs 17%, p = 0.02).

Conclusions

By implementing and continuously improving a standard process in the NICU and HRIF, we demonstrated a successful increase in screening for CP leading to a lower age at diagnosis sustained for two years.